About this item:

20 Views | 2 Downloads

Author Notes:

Corresponding author. eimarti@emory.edu (E.I. Martin).

C.B.N currently serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP), AstraZeneca, NARSAD, Quintiles, Janssen/Ortho-McNeil, and PharmaNeuroboost.

He holds stock/equity in Corcept; Revaax, NovaDel Pharma, CeNeRx, and PharmaNeuroboost.

He is on the board of directors of the AFSP, George West Mental Health Foundation, NovaDel Pharma, and Mt. Cook Pharma, Inc.

He holds a patent on the method and devices for transdermal delivery of lithium (US 6,375,990 B1) and the method for estimating serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April, 2001).

E.B. is co-inventor on the following patent applications: FKBP5: a novel target for antidepressant therapy, international publication number: WO 2005/054500; and Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments, international application number: PCT/EP2005/005194.

Subjects:

Research Funding:

This work was supported by National Institute of Health (NIH) grants MH-541380, MH-77083, MH-69056, MH-58922, MH-42088, MH071537, and DA-019624; the Doris Duke Clinical Scientist Award, and the Burroughs Wellcome Fund.

K.J.R. has received awards and/or funding support from Lundbeck, Burroughs Wellcome Foundation, Pfizer, the National Alliance for Research in Schizophrenia and Depression (NARSAD), the National Institute of Mental Health (NIMH), and the National Institute on Drug Abuse and has a consulting agreement with Tikvah Therapeutics for N-methyl-D-as-partic acid–based therapeutics.

In the past year, C.B.N also served on the Scientific Advisory Board for Forest Laboratories, received grant support from the NIMH, NARSAD, and AFSP, and served on the Board of Directors of the American Psychiatric Institute for Research and Education.

E.B. receives grant support from NARSAD and the Doris Duke Charitable Foundation.

In the past 2 years, she has received grant support from Pfizer Pharmaceuticals (Young Investigator award) and GlaxoSmithKline.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Psychiatry
  • Amygdala
  • Generalized anxiety disorder
  • Posttraumatic stress disorder
  • Panic disorder
  • Social anxiety disorder
  • Corticotropin-releasing factor
  • POSTTRAUMATIC-STRESS-DISORDER
  • CORTICOTROPIN-RELEASING HORMONE
  • BENZODIAZEPINE-RECEPTOR-BINDING
  • PREFRONTAL CORTEX ACTIVATION
  • PREDICTS TREATMENT RESPONSE
  • PANIC DISORDER
  • SEROTONIN TRANSPORTER
  • MAJOR DEPRESSION

The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology

Tools:

Journal Title:

Psychiatric Clinics of North America

Volume:

Volume 32, Number 3

Publisher:

, Pages 549-+

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Anxiety disorders are highly comorbid with each other and with major depressive disorder. As syndromes, anxiety and mood disorders share many symptoms, and several treatments are effective for both. Despite this overlap, there exist many distinguishing features that support the continued classification of individual anxiety disorders that are distinct from each other and from major depression. The goal of this article is to describe the key biological similarities and differences between anxiety disorders.

Copyright information:

© 2009 Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote